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ABSTRACT
Objective: To develop consensus recommendations for reporting of quantitative optical coher-
ence tomography (OCT) study results.
Methods: A panel of experienced OCT researchers (including 11 neurologists, 2 ophthalmolo-
gists, and 2 neuroscientists) discussed requirements for performing and reporting quantitative
analyses of retinal morphology and developed a list of initial recommendations based on experi-
ence and previous studies. The list of recommendations was subsequently revised during several
meetings of the coordinating group.
Results: We provide a 9-point checklist encompassing aspects deemed relevant when reporting
quantitative OCT studies. The areas covered are study protocol, acquisition device, acquisition
settings, scanning protocol, funduscopic imaging, postacquisition data selection, postacquisition
data analysis, recommended nomenclature, and statistical analysis.
Conclusions: The Advised Protocol for OCT Study Terminology and Elements recommendations
include core items to standardize and improve quality of reporting in quantitative OCT studies.
The recommendations will make reporting of quantitative OCT studies more consistent and in line
with existing standards for reporting research in other biomedical areas. The recommendations
originated from expert consensus and thus represent Class IV evidence. They will need to be reg-
ularly adjusted according to new insights and practices. Neurology® 2016;86:2303–2309
GLOSSARY
APOSTEL 5 Advised Protocol for OCT Study Terminology and Elements; GEE 5 generalized estimating equation models;
IMSVISUAL 5 International Multiple Sclerosis Visual;MS 5 multiple sclerosis; OCT 5 optical coherence tomography; ON 5
optic neuritis.
Optical coherence tomography (OCT) utilizes near infrared light to generate high-resolution
cross-sectional images of biological tissue.1 Since its development, OCT has been used for the
diagnosis and monitoring of numerous primary ocular diseases. With ongoing enhancement of
resolution in newer devices and the development of powerful and reliable image processing
algorithms, OCT is being increasingly employed to measure the effects of axonal and neuronal
damage caused by retinal diseases and optic neuropathies. In recent years, such a quantitative
approach has extended the application of OCT to many neurologic disorders with known damage
to the visual pathway with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders
being the most important. OCT is a sensitive tool for tracking structural changes of the retina,
*These authors contributed equally to this work as first/senior authors.
From the Multiple Sclerosis Center (A.C.-H., P.V., A.J.G.), Department of Neurology, University of California San Francisco; Departments of
Neurology and Ophthalmology (L.J.B., A.P.), VU University Medical Centre, Amsterdam, the Netherlands; Charité–Universitätsmedizin Berlin
(T.O., F.P., A.U.B.), NeuroCure Clinical Research Center; Department of Neurology (T.O., F.P., A.U.B.), Experimental and Clinical Research
Center, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Neurology (S.S., P.C.), Johns Hopkins University,
Baltimore, MD; Center of Neuroimmunology and Department of Neurology (E.H.M.-L., P.V.), Institut d’Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain; Eye Center (W.A.L.), University Medical Center, Freiburg, Germany; Departments of
Ophthalmology (J.S.S.) and Neurology (L.B.), New York University School of Medicine, New York; Moorfields Eye Hospital and The National
Hospital for Neurology and Neurosurgery (A.P.), London, UK; and Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine University
Düsseldorf, Germany.
Coinvestigators are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article processing charge was paid by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially.
© 2016 American Academy of Neurology 2303
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
including the macula and optic nerve head, in
inflammatory,2–7 degenerative,8–12 vascular,13,14
and metabolic15 diseases of the CNS.
AIMS ANDUSE As the number of quantitative OCT
studies in neurology rapidly increases (more than 500
articles reported in PubMed to date) and varying de-
vices and image processing technologies have come
into play, there is a need for the development of con-
sistent and coherent standardized reporting recom-
mendations. Harmonious reporting is important for
a critical assessment of the strengths and weaknesses
of a study. In previous studies, ambiguous reporting
has led to uncertainty about different methodologic
aspects, such as scan protocols, the use of quality con-
trol criteria, and inclusion or exclusion of patients or
eyes. The lack of more detailed information on such
topics limits the ability to compare data and to apply
and generalize findings from these studies. Herein, we
present the Advised Protocol for OCT Study Termi-
nology and Elements recommendations (APOSTEL
recommendations). They have been developed to
outline core information that should be provided
when reporting quantitative OCT studies. As such,
the recommendations will be instructive for research-
ers reporting OCT studies that quantitatively assess
retinal layer thicknesses and related data. Adhering
to these recommendations will improve interstudy
interpretability and comparability, ultimately helping
to advance research and the clinical application of
OCT in the study of neurologic diseases.
The APOSTEL recommendations are designed to
complement existing and well-established reporting
guidelines16 openly available through the equator net-
work (http://www.equator-network.org), but add spe-
cific parameters for the reporting of OCT data. We
encourage authors to consider the APOSTEL recom-
mendations when quantitative OCT data are to be
reported in a study. Likewise, we invite reviewers and
journal editors to support adherence to these recom-
mendations when considering OCT studies for publi-
cation. In table 1, we provide a quick and easy-to-use
checklist of the APOSTEL recommendations.
DEVELOPMENT The APOSTEL recommendations
were conceived during convened meetings of the authors
at the 2015 European Academy of Neurologymeeting in
Berlin, Germany. In these meetings, the aims and scopes
of the recommendations were discussed and working
groups were established. A preliminary version of the
manuscript and the checklist was generated by the
working groups, discussed and approved during a joint
telephone conference, and then circulated to the
members of the International Multiple Sclerosis Visual
(IMSVISUAL) consortium (http://www.imsvisual.org)
in several rounds for comments and revisions. The
members of the consortium approved the final
manuscript in person during the 2015 European
Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) convention in Barcelona, Spain,
or by e-mail in the case of those who could not attend the
meeting.
APOSTEL RECOMMENDATIONS Describe the study
protocol. The study design including the inclusion and
exclusion criteria and the demographics of the study
participants should be described according to estab-
lished reporting guidelines as may already be appli-
cable to the study, e.g., the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE), Consolidated Standards of Reporting
Trials (CONSORT), or Case Reports (CARE)
guidelines.16 Additional information is required for
OCT studies, which generally include information
regarding both eyes of each participant. With respect
to inclusion and exclusion criteria, authors should
define if these were applied at the eye or patient level.
In OCT studies, coexisting ocular pathologies repre-
sent potential confounders, which can have profound
impact on results. Therefore, the patient history and
examinations performed to exclude confounding
ocular pathologies such as glaucoma or macular
degeneration, e.g., funduscopy, tonometry, or slit-
lamp examinations (for a complete list see reference
17), should be described. We also advise reporting
whether patients were tested for refractive errors as
well as the cutoff for exclusion based on refraction
(typically 66 D).18 The numbers of eyes and
patients excluded should be reported, as well as the
criteria leading to such exclusions. In studies
comparing OCT examinations to other assessments,
e.g., clinical scores or other imaging modalities, it is
important to report the time interval between
assessments. For OCT studies of neuroinflammatory
diseases, reporting the history of and time span from
a previous optic neuritis (ON), as well as the number of
ON episodes, is of major importance. The authors
should clearly define how history of ON was assessed.
We strongly recommend the use of standardized
definitions of ON19 including information on whether
previous ON diagnoses were arrived at based on
clinical,20 electrophysiologic, or structural assessments.19
State the acquisition device type, name, and version.
OCT technology has greatly advanced in recent years.
Commercially available OCT devices differ in their
optics, data acquisition characteristics, and image anal-
ysis algorithms.21 It is important to provide detailed
information on the devices used (manufacturer, model,
interferometric technique), especially in the case of
multicenter studies. In addition, detailed information
on the software (type, version) used for the acquisition
should be provided, if applicable. Wavelength should
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Table 1 Nine-point Advised Protocol for OCT Study Terminology and Elements checklist
Item Recommendation
1 Study protocol Describe how many OCT operating sites and graders were included ❑
Report the timing of OCT compared to other measurements (same day, delayed) ❑
Describe the inclusion and exclusion criteria ❑
2 Acquisition device For all OCT devices used, report data on:
Manufacturer ❑
Model ❑
Version ❑
Software version ❑
3 Acquisition Settings Clearly describe the settings in which OCT scans were obtained:
Room light conditions ❑
Pupils dilated before examination (y/n) ❑
Number of operators and devices ❑
4 Scanning protocol Clearly describe the scanning protocol, including:
Type of scan (circular, volume, star, line, other) ❑
Location (area of interest, macula, optic nerve head, papillomacular bundle, other?) ❑
Scan parameters (with or without eye tracking) ❑
Volume scan: size of scan area (degrees or millimeters), number of B-scans, alignment of B-scans, number
of A-scans per B-scan
Radial scan: size of scan area (degrees or millimeters), number of B-scans, alignment of B-scans, number
of A-scans per B-scan
Ring scan: diameter, A-scans/B-scan, manual or automatic placement of ring or method of centering,
depth resolution
Line scan: angle, location, number of A-scans, depth resolution
5 Funduscopic imaging Report other imaging modalities used in addition to OCT (funduscopy, confocal scanning laser
ophthalmoscopy, retinal angiography, autofluorescence imaging)
❑
Describe acquisition protocol, including: ❑
Excitation wavelength ❑
Filter sets ❑
Number of frames averaged (if applicable) ❑
6 Postacquisition data selection Describe image selection process, including: ❑
Quality control criteria (i.e., OSCAR-IB17 or other criteria) ❑
Postacquisition discard (number and criteria) ❑
Eye selection strategy (if applicable) ❑
7 Postacquisition analysis Describe all postacquisition steps:
Software used for processing scans and segmentation (may be different from acquisition software) ❑
Which individual retinal layers were segmented/included ❑
Method of segmentation (automated, semiautomated, or manually) ❑
How potential bias was addressed in the case of manual segmentation (masking) ❑
Grid used for data extraction (size, shape, selected sections) ❑
8 Nomenclature and abbreviations Define:
Anatomical structures analyzed ❑
Units of provided measurements (e.g., volume or thickness) ❑
9 Statistical approach Describe:
Statistical models used for the analyses of OCT data ❑
Whether data were analyzed by eye or by patient ❑
Abbreviation: OCT 5 optical coherence tomography.
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be specified, particularly for studies using prototype
OCT devices, as different OCT wavelengths may have
different imaging characteristics.
Define the acquisition setting. The conditions under
which OCT measurements were performed should
be standardized and reported. First, the number of
individual operators and OCT devices should be re-
ported (sites with more than one operator might
describe the intraoperator and interoperator repro-
ducibility of OCT measurements at their sites).
Second, there has been some debate over the necessity
of pupil dilation. There is concern that pupil dilation
might decrease reliability due to higher beam place-
ment variation.22 However, the actual effects of pupil
dilation have not yet been definitively determined
and may in fact be ambiguous.23 For example, some
patients, especially with severe visual or cognitive
impairment, might only be assessable by OCT after
pupil dilation.24 Handling of pupil dilation should
therefore be reported. Finally, several OCT devices
offer differing methods for correcting eye movement
or position change during acquisition and follow-up
measurements. If such a method was used, its
application should be reported.
Define OCT scanning protocol. Different OCT scan-
ning protocols influence volumetric imaging and
morphometric results.25 Often, an OCT imaging ses-
sion consists of several scan acquisitions per eye.
Thus, it is essential to report relevant acquisition pa-
rameters of the full measurement protocol, including
all scan types employed in a study. The target struc-
ture for each scan should be defined and named (e.g.,
retinal nerve fiber layer, macula, optic nerve). Each
scan’s shape (e.g., ring, line, volume, radial), orienta-
tion (e.g., horizontal, vertical), and size (in degrees or
millimeters), as well as other relevant scan-specific
parameters, should be reported. For all scans, the
authors should provide information on the number
of total B-scans, the number of A-scans used for each
B-scan, and the number of B-scans averaged.
Define funduscopic imaging. Many OCT devices offer
additional fundus imaging modalities such as confocal
scanning laser ophthalmoscopy, retinal angiography,
and autofluorescence imaging. If included in the anal-
ysis, these should be described and the acquisition
protocol including the excitation wavelength, filter
sets, and the number of frames averaged (if applica-
ble) indicated.
Describe postacquisition data selection. Many OCT
image postprocessing algorithms (either included
within the device or as external software) have high de-
mands in terms of image contrast and quality. To
improve the reliability of results, studies often employ
some form of image selection process. A common
strategy for increasing image and data quality includes
the averaging of several images or obtained values. Like-
wise, some studies record several images of the same tar-
get and subsequently use the optimal image based on
defined selection criteria. If such strategies were applied,
they should be described in detail, including the selection
criteria. In order to ensure a high quality of scans, the use
of quality control criteria is recommended. For example,
an extensive set of quality control criteria has been pub-
lished in the form of the OSCAR-IB criteria.17,26 Any
postacquisition discard should be reported including the
number and criteria leading to exclusion of the respective
scans. Cutoffs of quantifiable variables such as signal
strength should be clearly defined and stated.
Numerical values for signal strength are provided in
different units and scaling by the different devices so
separate cutoffs should be given if more than one
device type is used. Depending on the statistical
approach (see below), it might be necessary to exclude
eyes from the analysis. If this is the case, the strategy of eye
selection for statistical analysis should also be reported.
Describe postacquisition data analysis. After acquisition,
images have to be further processed and analyzed. Since
processing of images is not only device-specific but also
dependent on software-implemented algorithms, the
name of the software package and its version should
be indicated. Authors should report whether the
postprocessing performed (e.g., intraretinal layer
segmentation) was fully automated, semiautomated
with manual correction of obvious errors, or fully
manual. In the case of manual postprocessing,
authors should report the number of graders, and
indicate whether they were masked. Currently, the
main postprocessing analysis for retinal OCT data is
the generation of volume or thickness data derived
from the retinal layers. While data derived from
line and ring scans are commonly reported in
micrometers, the results derived from volume scans
can be reported as mean thickness in mm or volume
in mm3. We advise against the use of other units for
thickness and volume measurements unless explained
in the study objectives. To obtain such measurements,
differently sized or shaped areas can be used, such as the
ring-shaped grid defined for the Early Treatment
of Diabetic Retinopathy Study.27 As a matter of
fact, values derived from different areas or scans are
not necessarily comparable and might also show
differences with regard to reliability.28 Thus, area
shape and size, as well as the source scan used for
analysis, should be reported.
Use common nomenclature and abbreviations. The au-
thors should clearly define and describe all structures
analyzed. We recommend the nomenclature and ab-
breviations in table 2 and the figure. Adherence to the
nomenclature is especially important when referring
2306 Neurology 86 June 14, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
to composite structures. Authors should additionally
indicate in which scale structure measurements are
provided (e.g., volume or thickness). If authors need
to define additional composite structures, the exact
definition should be reported.
Define the statistical approach with exact model
description. For reporting statistical analyses, authors
should adhere to the recommendations in the applicable
reporting guidelines.16 Regarding the statistical features
of OCT studies, the following additional information
should be provided. As OCT scans are usually acquired
for both eyes in one participant, it is important to
describe any strategy applied to account for intereye
within-patient dependencies. This latter usually
includes either randomly selecting one eye or
estimating the mean for non-ON eyes or applying
statistical methods able to account for these
dependencies, such as general mixed effects models or
generalized estimating equation models (GEE).
Different strategies might be required for specific
questions.29 When advanced statistical models are used,
authors should report them in sufficient detail, i.e., the
model composition and relevant model configurations
such as the working correlation matrix in GEE.
IMPLICATIONS AND LIMITATIONS The aim of the
APOSTEL recommendations is to provide a consistent
basis for assisting authors in composing conclusive re-
ports of studies utilizing quantitative retinal OCT, al-
lowing relevant comparisons across and between
studies, and helping readers, reviewers, and editors to
evaluate these findings. Furthermore, by emphasizing
details that are of importance in such reports, we hope
to generally improve the quality of future investigations
in this area. Defining the relevant parameters for re-
porting may prompt researchers to thoroughly con-
sider these criteria during the initial stages of study
design. Such an approach could help facilitate OCT
research in centers intending to incorporate OCT for
clinical trials or other research purposes. Adherence
to the recommendations can help avoid common
pitfalls in the design and reporting of OCT studies.
These recommendations are not intended to impose
a rigid format on reports of OCT-based research,
but rather to provide suggestions and guidance on
which reporting standards to prioritize. As such,
the APOSTEL recommendations are intended to
complement existing reporting guidelines for clinical
studies.
The recommendations should be considered level
of evidence IV. They are not based on a systematic
review of the literature, but instead rely on the experi-
ence of IMSVISUAL’s authors and members in con-
ducting, reviewing, and reporting OCT studies. For
most of the aspects deemed relevant, formal experi-
mental evidence on their influence on OCT results is
lacking, preventing a meta-analytical approach or even
a comprehensive review of literature.
The recommendations were not derived from
a formalized consensus-building procedure like that
of a Delphi process, where anonymized question-
naires are circulated and evaluated in several rounds
to achieve consensus. The number of participating in-
dividuals was therefore naturally limited and was
influenced by existing networks or collaborations of
the authors. We acknowledge that this approach
can only generate a limited level of evidence (Class
IV). However, given the multiple dimensions of the
topic and initial heterogeneity of opinions, it was nec-
essary to establish consensus and standardization first.
We therefore purposefully chose the term recommen-
dation over guidelines. In order to increase the level of
evidence, we plan to refine, evaluate, and validate
these recommendations by means of a more formal
approach involving a larger forum of researchers to
develop more evidence-based guidelines.
Apart from validation, several other concerns need
addressing. For example, a limitation of the current
recommendations is that they were established by
a consortium dominated by neurologists and mainly
pertain to the quantitative detection and analysis of
retinal changes. Furthermore, the IMSVISUAL con-
sortium is predominantly focused on MS research.
Table 2 Proposed consensus nomenclature and abbreviations of retinal
structures and layers
Abbreviation Included structures and layers
RNFL Retinal nerve fiber layer
GCL Ganglion cell layer
IPL Inner plexiform layer
INL Inner nuclear layer
OPL Outer plexiform layer
ONL Outer nuclear layer
PRL Photoreceptor layer (external limiting membrane to retinal pigment epithelium);
this layer can be separated into the inner segment (IS) and outer segment (OS)
ISOS Inner and outer segments junction
OPT Outer photoreceptor tips
RPE Retinal pigment epithelium
ILM Inner limiting membrane
ELM External limiting membrane
BM Bruch membrane
ONH Optic nerve head
GCC Ganglion cell complex (composite of macular RNFL, GCL, and IPL)
GCIP or
GCIPL
Ganglion cell and inner plexiform layer (composite of macular GCL and IPL,
referred to as GCIP or GCIPL in the literature)
OPNL Outer plexiform and nuclear layer (composite of OPL and ONL)
TRT Total retinal thickness (ILM to BM), also named TMT or TMVwhen referring to the
total macular thickness or volume
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However, several of the authors are involved in OCT
research well beyond MS10,12–15,30 and the recommen-
dations have been designed to also apply to studies on
patients with other neurologic or ophthalmologic
conditions that are increasingly being performed with
similar methodology. Further development incorpo-
rating these potentially different points of view will be
crucial for the broader application and success of the
recommendations.
We therefore consider the APOSTEL recommen-
dations as a preliminary but urgently needed step
towards further improving the overall quality and util-
ity of quantitative OCT research in neurologic disor-
ders. These recommendations constitute an expert
consensus statement and their value will be assessed
in the future through use in studies related to visual
outcomes in ocular and neurologic disease. The recom-
mendations will require ongoing refinement to
increase the level of evidence and to accommodate
the continuous evolution of OCT technology. We will
update these recommendations in the future, taking
into account user comments, criticism, new evidence,
and experience. We therefore welcome suggestions
for improvement and further development of the crite-
ria, as well as additional areas of application, and invite
readers to submit their comments via the IMSVISUAL
Web site. Recommendation updates and current
checklist versions will be available on the IMSVISUAL
Web site (www.imsvisual.org).
AUTHOR CONTRIBUTIONS
Andrés Cruz-Herranz: study concept and design, acquisition of data,
analysis and interpretation, critical revision of the manuscript for impor-
tant intellectual content. Lisanne J. Balk: study concept and design,
acquisition of data, analysis and interpretation, critical revision of the
manuscript for important intellectual content. Timm Oberwahrenbrock:
analysis and interpretation, critical revision of the manuscript for impor-
tant intellectual content. Shiv Saidha: analysis and interpretation, critical
revision of the manuscript for important intellectual content. Elena H.
Martinez-Lapiscina: analysis and interpretation, critical revision of the
manuscript for important intellectual content. Wolf A. Lagreze: analysis
and interpretation, critical revision of the manuscript for important intel-
lectual content. Joel S. Schuman: analysis and interpretation, critical
revision of the manuscript for important intellectual content. Pablo Vil-
loslada: analysis and interpretation, critical revision of the manuscript for
important intellectual content. Peter Calabresi: analysis and interpreta-
tion, critical revision of the manuscript for important intellectual content.
Laura Balcer: analysis and interpretation, critical revision of the manu-
script for important intellectual content. Axel Petzold: analysis and inter-
pretation, critical revision of the manuscript for important intellectual
content. Ari J. Green: analysis and interpretation, critical revision of
the manuscript for important intellectual content. Friedemann Paul:
analysis and interpretation, critical revision of the manuscript for impor-
tant intellectual content. Alexander U. Brandt: analysis and interpreta-
tion, study concept and design, acquisition of data, critical revision of the
manuscript for important intellectual content, study supervision. Philipp
Albrecht: analysis and interpretation, study concept and design, acquisi-
tion of data, critical revision of the manuscript for important intellectual
content, study supervision.
ACKNOWLEDGMENT
The authors thank IMSVISUAL and its members for their input into the
development of these reporting guidelines.
STUDY FUNDING
No targeted funding reported.
Figure The consensus nomenclature for retinal structures
The different layers (and the borders of these) specified in table 2 are illustrated in a central vertical scan through the middle of the foveola. BM 5 Bruch
membrane; ELM 5 external limiting membrane; GCIP(L) 5 ganglion cell and inner plexiform layer; GCL 5 ganglion cell layer; ILM 5 inner limiting membrane;
INL 5 inner nuclear layer; IPL 5 inner plexiform layer; IRL 5 inner retinal layer; ISOS 5 inner and outer segments; ONL 5 outer nuclear layer; OPNL 5 outer
plexiform and nuclear layer; OPL 5 outer plexiform layer; OPT 5 outer photoreceptor tips; RNFL 5 retinal nerve fiber layer; RPE 5 retinal pigment epithelium.
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